Automate Your Wheel Strategy on MCRB
With Tiblio's Option Bot, you can configure your own wheel strategy including MCRB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MCRB
- Rev/Share 0.0
- Book/Share 0.3247
- PB 21.8328
- Debt/Equity 1.7745
- CurrentRatio 2.1096
- ROIC -0.8216
- MktCap 61912858.0
- FreeCF/Share -0.5587
- PFCF -0.7132
- PE 15.1032
- Debt/Assets 0.5454
- DivYield 0
- ROE 266.7313
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MCRB | Chardan Capital Markets | Buy | Neutral | -- | $6 | May 8, 2025 |
News
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2025 Earnings Call May 7, 2025 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Thorell - Chief Financial Officer Matthew Henn - Chief Scientific Officer Terri Young - Chief Commercial and Strategy Officer Dennis Walling - Senior Vice President, Clinical Development Conference Call Participants Caroline Pötsch-Hennig - JPMorgan Joseph Thome - TD Cowen John Newman - Canaccord Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Read More
Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript
Published: March 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi - Kendall Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Executive Vice President and Chief Medical Officer Matthew Henn - Executive Vice President and Chief Scientific Officer Terri Young - Executive Vice President, Chief Commercial and Strategy Officer Marella Thorell - Executive Vice President and Chief Financial Officer Chris McChalicher - Senior Vice President, Manufacturing, Quality and Process Development Conference Call Participants Joseph Thome - TD Cowen Caroline Pocher - JPMorgan Edward Tenthoff - …
Read More
About Seres Therapeutics, Inc. (MCRB)
- IPO Date 2015-06-26
- Website https://www.serestherapeutics.com
- Industry Biotechnology
- CEO Mr. Eric D. Shaff M.B.A.
- Employees 103